Literature DB >> 9801830

Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin.

F Anizon1, P Moreau, M Sancelme, A Voldoire, M Prudhomme, M Ollier, D Sevère, J F Riou, C Bailly, D Fabbro, T Meyer, A M Aubertin.   

Abstract

The indolocarbazole antibiotics staurosporine and rebeccamycin (1) are potent antitumor drugs targeting protein kinase C and topoisomerase I, respectively. To obtain staurosporine analogues from rebeccamycin, different structural modifications were performed: coupling of the sugar moiety to the second indole nitrogen, dechlorination and then reduction of the imide function to amide. The newly synthesized compounds (3-6) were tested for their abilities to bind to DNA and to inhibit topoisomerase I and protein kinase C. Their antiproliferative effects in vitro against B16 melanoma and P388 leukemia (including the related P388CPT cell line resistant to camptothecin) as well as their anti-HIV-1 and antimicrobial activities against various strains of microorganisms were determined. The cytotoxicity of the dechlorinated imide analogue 5 correlates well with its DNA binding and anti-topoisomerase I activities. These findings provide guidance for the development of new topoisomerase I-targeted antitumor indolocarbazoles equipped with a carbohydrate attached to the two indole nitrogens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801830     DOI: 10.1016/s0968-0896(98)00096-0

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.

Authors:  Gautam Borthakur; Yesid Alvarado; Farhad Ravandi-Kashani; Jorge Cortes; Zeev Estrov; Stefan Faderl; Percy Ivy; Carlos Bueso-Ramos; B Nebiyou Bekele; Francis Giles
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

2.  Structure elucidation and anticancer activity of 7-oxostaurosporine derivatives from the Brazilian endemic tunicate Eudistoma vannamei.

Authors:  Paula Christine Jimenez; Diego Veras Wilke; Elthon Gois Ferreira; Renata Takeara; Manoel Odorico De Moraes; Edilberto Rocha Silveira; Tito Monteiro Da Cruz Lotufo; Norberto Peporine Lopes; Leticia Veras Costa-Lotufo
Journal:  Mar Drugs       Date:  2012-05-21       Impact factor: 6.085

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.